In the KeyNote-010 trial the effects of pembrolizumab at 2 or 10 mg/kg Q3W were compared to docetaxel (75 mg/m2 Q3W) in patients with advanced or metastatic NSCLC with PD-L1 expression (≥1%). This evidence concerns the gene CD274 and non-small cell lung carcinoma.